Allakos is conducting a clinical study to test the safety and efficacy of an experimental drug AK002 for eosinophilic gastrointestinal diseases (EGIDs).
This study is currently recruiting in Adelaide.
Eosinophilic esophagitis (EoE) is a chronic, inflammatory disease characterized by high levels of mast cells and eosinophils (two types of immune system cells) in the esophagus (muscular tube connecting the mouth to the stomach). This study will test whether AK002 can reduce eosinophils in the blood and the tissue of the esophagus and help improve symptoms.
Females and males, age 18 to 80 years old who have a confirmed diagnosis of EoE and/or think they may have EoE (experiencing symptoms including difficulty swallowing or discomfort when swallowing), may be eligible for this study.
More information available on this flyer.
To learn more about this study, please call Jane at Lyell McEwin Hospital on 08 8182 9493
Page last modified: 23 March, 2021